Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans (NMDAR)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- healthy volunteers
Exclusion Criteria:
- history of psychiatric, medical, neurological illness or substance abuse
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: D-serine
single P.O.
administration of D-serine (2.1g)
|
single P.O.
administration of D-serine (2.1g)
Other Names:
|
|
Placebo Comparator: Placebo
single P.O.
administration of corn starch
|
single P.O.
administration of Placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours
Time Frame: Baseline, 2 hours post intervention
|
The subject was asked to point on the VAS scale according to his anxiety level.
VAS anxiety scale 0 to 10 ( 0 [no anxiety] to 10 [maximum anxiety] ).
|
Baseline, 2 hours post intervention
|
|
Change in Cognitive Function- CPT-IP D-prime Score - From Baseline to 2 Hours
Time Frame: Baseline, 2 hours post intervention
|
The "d-prime score" is a score given to each participant on a scale of 0.0 - 1.0 in which discrimination sensitivity is measured.
A score of 0 equates to no sensitivity whereas a score of 1.0 equates to perfect sensitivity.
|
Baseline, 2 hours post intervention
|
|
Change in Rey Auditory Verbal Learning Test RAVLT (Trial 7) - From Baseline to 2 Hours
Time Frame: Baseline, 2 hours post intervention
|
RAVLT measures short term verbal memory, verbal learning, susceptibility to (proactive and retroactive) interference, retention of information after a certain period of time during which other activities are performed and recognition memory.
The test consists of a list of 15 common nouns, which are read to the subject in five consecutive trials (trials 1 through 5); each reading is followed by a free-recall task.
In trial 6, an interface list of 15 new common nouns is presented, followed by free recall of these new nouns.
In trial 7, without additional reading, subjects are again asked to recall the first list.
Twenty minutes later, without an additional reading, subjects are asked to recall once more the first list (trial 8).
The RAVLT score range from 0-90 correctly recalled words.
For trial 7 the score ranges from 0 to 15 correctly recalled words.
|
Baseline, 2 hours post intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Uriel Heresco-Levy, M.D., Herzog Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 112-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.